Obstetrics and Gynecology
Tuberculosis in Pregnancy
1. What every clinician should know
Tuberculosis (TB) is caused by a bacterium called mycobacterium tuberculosis. This microorganism is a highly aerobic, acid-fast staining rod. The bacteria usually infect the lungs, but may infect any part of the body, including the kidney, spine, and brain. If not treated, TB can be fatal.
Nearly one-third of the world's population is infected with TB. In 2010, 9 million people around the world became infected with TB, and there were approximately 1.4 million TB-related deaths. TB is a leading killer of people who are HIV infected. A total of 11,182 TB cases (a rate of 3.6 cases per 100,000 persons) were reported in the United States in 2010. Both the number of reported TB cases and the case rate have decreased; there was a 3.1% decline in TB cases compared to 2009.
TB is spread through the air from one person to another. The bacteria may become aerosolized when an infected individual coughs, sneezes, or sings. People nearby may breathe in these aerosolized bacteria and become infected. TB is not spread by hand shaking, sharing food or drink, touching bed linens or toilet seats, sharing toothbrushes, or kissing.
Not everyone infected with TB becomes sick. The two TB-related conditions are active TB and latent TB infection.
People with latent TB do not feel sick and do not have symptoms. The only sign of TB infection is a positive reaction to the tuberculin skin test or special TB blood test. People with latent TB are not contagious and cannot spread TB to others. However, people with latent TB can develop active TB, causing symptoms and facilitating spread.
When tuberculosis becomes active, 75% of cases involve infection in the lungs. Symptoms include chest pain, hemoptysis, and a productive, prolonged cough for more than 3 weeks. Systemic symptoms include fever, chills, night sweats, appetite loss, weight loss, pallor, and fatigue.
In the United States, African-Americans, individuals in correctional facilities, and those infected with HIV infected make up a disproportionate share of TB cases.
2. Diagnosis and differential diagnosis
The Mantoux tuberculin skin test (TST) is the standard method of determining whether a person is infected with M. tuberculosis. The TST is performed by injecting 0.1 ml of tuberculin purified protein derivative (PPD) into the inner surface of the forearm. The injection should be made with a tuberculin syringe, with the needle bevel facing upward.
The TST is an intradermal injection. When placed correctly, the injection should produce a pale elevation of the skin (a wheal) 6-10 mm in diameter. The skin test should be read between 48 and 72 hours after administration. A patient who does not return within 72 hours will need to be rescheduled for another skin test.
The reaction should be measured in millimeters of the induration (palpable, raised, hardened area or swelling). The reader should not measure erythema. The diameter of the indurated area should be measured across the forearm (perpendicular to the long axis).
The skin test interpretation depends on two factors: measurement of the induration (in millimeters) and the person's risk of being infected with TB and, if infected, of progression to disease.
Classification of the Tuberculin Skin Test Reaction
|An induration of 5 or more millimeters is considered positive in: HIV-infected personsA recent contact of a person with TBPersons with fibrotic changes on chest radiograph, consistent with prior TBPatients with organ transplantsPersons who are immunosuppressed for other reasons (e.g., taking the equivalent of >15 mg/day of prednisone for 1 month or longer, taking TNF-a antagonists)||An induration of 10 or more millimeters is considered positive in Recent immigrants (< 5 years) from high-prevalence countriesInjection drug usersResidents and employees of high-risk congregate settingsMycobacteriology laboratory personnelPersons with clinical conditions that place them at high riskChildren < 4 years of ageInfants, children, and adolescents exposed to adults in high-risk categories||An induration of 15 or more millimeters is considered positive in any person, including persons with no known risk factors for TB. However, targeted skin testing programs should only be conducted among high-risk groups.|
False positive reactions may occur in persons with infection with nontuberculosis mycobacteria, previous BCG vaccination, and incorrect TST method.
False negative reactions may occur in persons with cutaneous anergy, recent TB infection (within 8-10 weeks of exposure), very old TB infection (many years), recent live virus vaccination, overwhelming TB, and incorrect TST method.
A TB blood test (interferon-gamma release assays [IGRA]) is a measure of how the immune system reacts to M. tuberculosis. This test does not differentiate active from latent TB. The test is based on the observation that white blood cells from most people infected with TB will release interferon-gamma (IFN-g) when mixed with antigens derived from M. tuberculosis. A prior BCG (bacille Calmette-Guerin) vaccination does not cause a false-positive IGRA test result.
Untreated TB represents a greater hazard to a pregnant woman and her fetus than does its treatment. Treatment of pregnant women should be started when the chance of TB is moderate to high. Infants born to women with untreated TB may be of lower birth weight than those born to women without TB and, rarely, the infant may be born with TB. Although the drugs used in the initial treatment regimen cross the placenta, they do not appear to have harmful effects on the fetus.
The treatment of TB in pregnant women should be the same as that in nonpregnant women. The only exception is that aminoglycosides should be avoided in pregnancy, as they are ototoxic to the fetus.
Latent TB Infection (LTBI)
Isoniazid (INH) administered either daily or twice weekly for 9 months is the preferred regimen for treating LTBI in pregnant women. Women taking INH should also take pyridoxine (vitamin B6) supplementation.
Active TB Disease
Pregnant women should start treatment as soon as TB is suspected. The preferred initial treatment regimen is INH, rifampin (RIF), and ethambutol daily for 2 months, followed by INH & RIF daily or twice weekly for 7 months, for a total of 9 months of treatment. Streptomycin should not be used because it has been shown to have harmful effects on the fetus. In most cases, pyrazinamide (PZA) is not recommended because its effect on the fetus is unknown.
HIV-infected pregnant women who are suspected of having TB should be treated without delay. TB treatment regimens for HIV-infected pregnant women should include a rifamycin. Although the routine use of PZA during pregnancy is not recommended in the United States, the benefits outweigh the undetermined potential risks to the fetus.
Optimal treatment of HIV-associated TB requires treatment with 2 multidrug regimens, typically 6 months of a 4-drug then a 2-drug regimen, to treat TB and a lifelong 3-drug antiretroviral regimen to reverse the functional immunosuppression that resulted in the development of active TB and to halt the further acceleration of HIV disease induced by active TB. Three recent trials have demonstrated the safety and superiority of initiating ART as soon as 2 weeks after the initiation of treatment for active TB, rather than at intervals of >2 to 6 months later.
Aminoglycosides and the fluoroquinolone antituberculosis drugs are contraindicated in pregnant women. However, the management of multidrug resistant TB (MDR-TB) in pregnancy is complex, and there is limited data on the safety of second-line drugs in pregnancy. In a large retrospective analysis on the treatment of MDR-TB in pregnancy, fluroquinolones were commonly continued while injectable aminoglycosides were generally stopped. Women who are being treated for drug-resistant TB should receive counseling about the risk to the fetus from second-line antituberculosis drug therapy.
Breastfeeding should not be discouraged for women being treated with the first-line antituberculosis drugs because the concentrations of these drugs in breast milk are too small to produce toxicity in the nursing newborn. For the same reason, drugs in breast milk are not an effective treatment for TB disease or LTBI in a nursing infant. Breastfeeding women taking INH should also take pyridoxine (vitamin B6) supplementation.
Mother-to-child transmission of TB may occur in utero through hematogenous spread through the umbilical vein and aspiration or swallowing of infected amniotic fluid, and during the intrapartum period through contact with infected amniotic fluid or genital secretions.
Postpartum infection may occur through aerosol spread or infected breast milk from an active TB lesion in the breast. Although transmission through breast-feeding is negligible, an infant of a mother with active TB may still be infected through aerosol spread, even if formula fed.
5. Prognosis and outcome
There appears to be no statistically significant differences in pregnancy complications and pregnancy outcomes in pregnant women diagnosed and promptly treated for TB relative to matched controls who were pregnant and had no TB. Timely and appropriate treatment avoids the higher neonatal mortality rates associated with extreme prematurity in pregnancies with either untreated TB or when treatment is started late in the pregnancy.
Copyright © 2017, 2014 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)